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Background: Intermedin (IMD) is involved in the prevention of atherosclerotic plaque progression, possessing
cardioprotective effects from hypertrophy, fibrosis and ischemia-reperfusion injury. Elevated plasma IMD levels have
been demonstrated in patients with acute coronary syndromes. No human study has examined the role of IMD in
stable patients who underwent diagnostic coronary angiography with suspicion of coronary artery disease (CAD).
Thus we investigated the role of IMD as a biomarker to discriminate patients with CAD and predict those with
severe disease who require early and intensive therapeutic intervention before presenting with acute coronary
syndrome.
Methods: Eligible two hundred and thirty-eight consecutive patients (123 males, mean age 58.4 ± 10.0 years) who
underwent first-time diagnostic coronary angiography were included in this study. Plasma concentrations of IMD
were measured from arterial blood samples by the enzyme-linked immunosorbent assay. Patients were divided into
three groups according to the presence and degree of CAD, consisting of 48 patients with normal coronary
anatomy (Group 1), 111 patients with < 50% coronary stenosis (Group 2), and 79 patients with ≥ 50% stenosis in at
least one of the major coronary arteries (group 3). The severity and extent of CAD was evaluated by calculations of
the vessel, Gensini, and SYNTAX scores.
Results: Circulating plasma IMD levels in patients with CAD were significantly higher than those in patients without
CAD (157.7 ± 9.6, 134.8 ± 11.9, and 117.6 ± 7.9 pg/mL in groups 3, 2 and 1 respectively; p < 0.001). Besides, plasma
IMD levels were correlated with Gensini and SYNTAX scores (rs = 0.742, and rs = 0.296, respectively; p < 0.05). The
presence of ≥50% coronary artery stenosis could be predicted if a cut-off value of 147.7 pg/mL for plasma IMD was
used with 88.6% sensitivity and 88.7% specificity. Moreover, a plasma IMD level of <126.6 pg/mL could discriminate
a patient with normal coronary arteries from patients with angiographically proven CAD with a sensitivity and
specificity of 84.7%, and 83.3% respectively.
Conclusions: We demonstrated that IMD might be used as a biomarker to predict CAD and its severity in patients
who underwent first time diagnostic coronary angiography.
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Cardiovascular disease is the leading cause of morbidity
and mortality worldwide [1]. Although atherosclerosis is
the underlying pathology in general, there are many mecha-
nisms proposed to explain the development of the disease
from plaque formation to thrombus related occlusion of
the artery such as, inflammation, oxidative stress, and endo-
thelial dysfunction [2,3]. Identification and quantification of
atherosclerotic involvement is of high importance to deter-
mine patients at high risk for future cardiovascular events.
Nowadays, there is considerable evidence supporting the
clinical utility of several biomarkers, which are involved in
the development of atherogenesis, to determine the pro-
spective cardiovascular risk [4].
Intermedin (IMD) is a novel member of the calcitonin
gene-related peptide (CGRP) family, which serves as an
endocrine integrator of homeostasis in the cardiovascular
and renal systems [5]. It exerts directly positive inotropic
and chronotropic effects on the myocardium, besides IMD
reduces the cardiac afterload via systemic and pulmonary
vasodilatation, induces coronary vasodilatation, thereby
enhancing myocardial perfusion [6]. In addition, it has
been also reported to be cardioprotective from remodel-
ling by inhibiting cardiac fibroblast activation induced by
angiotensin II, anti-hypertrophic in conditions that pro-
mote cardiac myocyte hypertrophy, and protecting against
ischemia-reperfusion injury by inhibiting formation of re-
active oxygen species [5,7,8]. Furthermore, Zhang et al.
demonstrated that exogenous administration of IMD
could prevent the progression of atherosclerotic plaque
formation in ApoE null mice [9]. Two recent human stud-
ies, which investigated the role of IMD in acute coronary
syndromes, demonstrated that plasma levels of IMD were
markedly elevated in patients with acute myocardial in-
farction and moreover revealed that it could be used as a
marker to reflect the severity of coronary stenosis in this
patient collective [10,11].
To the best of our knowledge, there is not any data
about plasma IMD concentrations and its diagnostic
value in stable patients with signs and/or symptoms sug-
gesting coronary artery disease (CAD). The aim of this
study is to investigate the clinical relevance of plasma
IMD levels to predict CAD in patients who underwent
first-time diagnostic coronary angiography and its asso-
ciation with the severity and extent of the disease.
Methods
Study population
Patients enrolled in this study were patients who under-
went diagnostic conventional coronary angiography for
suspected CAD at our institution between February 1,
2013 and November 1, 2013. Exclusion criteria included
histories of recent myocardial infarction (MI), unstable an-
gina pectoris (UAP), heart failure (systolic and/or diastolicheart failure was excluded with the use of transthoracic
echocardiography, left ventricular ejection fraction <40%
was accepted as systolic heart failure), moderate to severe
heart valve disease, malignancies, major trauma or surgery
in the previous six months, renal insufficiency, acute or
chronic infectious disease, chronic obstructive pulmonary
disease, any kind of immune-mediated disease, since all
these conditions may affect plasma IMD levels. Patients
with coronary anomalies and/or slow flow phenomenon
were also excluded. According to the inclusion criteria two
hundred and thirty-eight eligible patients were included
into the study. The local ethics committee (BezmiÂlem
Foundation University Clinical Studies Ethics Committee)
approved the study protocol, and all patients provided an
informed consent. The study was conducted in accordance
with the ethical principles described by the Declaration of
Helsinki.
Coronary angiography
Coronary angiography was performed by a monoplane
cine-angiography system. Standard selective coronary
angiography with at least four views of the left coronary
system and two views of the right coronary artery had
been performed using the Judkins technique. All angio-
grams were recorded at a 25 frames/second rate by
using a 35 mm cinefilm and iopromide (Ultravist 370,
Schering AG, Berlin, Germany) was used as opaque ma-
terial. Two blinded experienced interventional cardiolo-
gists from our institute examined the angiograms. When
there was a disagreement, the difference was adjusted by
a third investigator.
Modified Gensini scoring system and the vessel score
were used to determine the severity and extent of CAD
[12,13]. To calculate the vessel score, one point was
assigned to each coronary artery when there was 50% or
more stenosis in the three main coronary arteries and
their major side branches [13]. One additional point was
assigned when there was 50% or more stenosis in the left
main coronary artery (LMCA), consequently with a total
score of maximum 4. On the other hand, modified Gen-
sini score was obtained by giving consideration to the
severity of lesions at certain segments of the LMCA, left
anterior descending (LAD), circumflex (Cx) and right
coronary (RCA) arteries [12]. Two points were assigned
for a lesion with an obstruction level between 0-24%, 4
points for a lesion of 25-49%, 8 points for a lesion of 50-
74%, 16 points for a lesion of 75-89%, 32 points for a
lesion of 90-99% and 64 points for a lesion of 100% ob-
struction. If the RCA was dominant, the lesion score for
LMCA was multiplied by a constant multiplier of 5; the
lesion scores for proximal LAD and Cx were multiplied
by 2.5; the score for medial LAD lesion was multiplied
by 1.5; the scores for RCA, distal LAD and distal
Cx lesions were multiplied by 1; the scores for optus
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multiplied by 1 and the lesion score for other side
branches was multiplied by 0.5. Total Gensini score was
obtained by adding the resultant figures. If the left
system was dominant, a constant multiplier of 0.5 multi-
plied the scores of proximal, medial and distal segment
lesions of the RCA. Ultimately, total Gensini score was
obtained numerically, indicating the severity of CAD. In
addition, the Synergy between PCI with Taxus and Car-
diac Surgery (SYNTAX) score was applied to all coron-
ary lesions with a diameter stenosis greater than 50% in
vessels with a dimater larger than 1.5 mm as described
before [14]. Inter- and intra-observer variability for
repeated evaluations of angiograms of 20 randomly
selected patients was low (for Gensini score: inter-
observer variability 4.1 ± 1.9%; intra-observer variability
4.4 ± 2.0%).
Laboratory tests
Peripheral blood samples for complete blood count and
serum creatinine, fasting glucose and lipid profiles were
taken from an antecubital vein in the morning before the
coronary angiography. All patients had normal serum cre-
atinine levels and normal white blood cell counts. Total
cholesterol, triglycerides, and high-density lipoprotein
cholesterol were measured using enzymatic methods after
overnight fasting. Low density lipoprotein (LDL) choles-
terol concentrations were calculated using the Friedewald
formula [15].
Arterial blood samples for IMD measurements were
collected in EDTA anticoagulant tubes from the arterial
sheath before coronary angiography. The samples were
centrifuged for 10 minutes at 4°C and 3000 g within 30 mi-
nutes after collection for separation of plasma. All plasma
samples were stored frozen at −40°C before use. Plasma
concentrations of IMD were measured by the enzyme-
linked immunosorbent assay (ELISA) kit, manufactured
by MyBioSource, Inc. (San Diego, USA). The intra- and
inter-assay coefficient of variation was less than 10% and
5% respectively. All procedures followed strictly the man-
ufacturer’s instructions.
Statistical analysis
Data were analyzed by using the SPSS software version
13.0 (SPSS, Chicago, IL). The distribution of the variables
was analyzed with the Kolmogorov–Smirnow test. Con-
tinuous, normally distributed variables were presented as
mean ± standart deviation (SD), and non-normally distrib-
uted variables as median (interquartile range). Categorical
and ordinal data were presented as frequencies and/or
percentages. Differences between groups were tested using
Student’s t test or Mann–Whitney U test. Categorical vari-
ables were compared by the χ2-test. The Spearman’s cor-
relation coefficient (rs) was computed to assess variablerelations. A regression analysis was performed to detect
the predictors of presence of angiographically confirmed
CAD. The univariated regression model was used separ-
ately for each following covariates: age, gender, smoking
status, BMI, hypertension, diabetes, dyslipidemia, and
serum IMD level. The covariates, which were significantly
associated with the presence of CAD in the univariated
model, were included into the multivariate logistic regres-
sion analysis. A two-sided p value < 0.05 was considered
statistically significant.
Results
Patients’ baseline characteristics were listed in Table 1.
Patients were divided into three groups according to the
presence and degree of luminal stenosis on coronary
angiography: 48 patients with normal coronary anatomy
(group 1), 111 patients with < 50% coronary stenosis
(group 2), and 79 patients with ≥ 50% stenosis in at least
one of the major coronary arteries (group 3). Patients with
CAD (groups 2 and 3) were mostly males and they were
significantly older than patients in group 1 (p < 0.05).
There was no significant difference in terms of BMI and
waist circumference. Besides, smokers were more com-
mon in group 2, but the difference did not reach any stat-
istical significance. However, traditional cardiovascular
risk factors, such as hypertension, diabetes, and hyperlip-
idemia were not different in patients with and without
CAD. Laboratory measures, including serum glucose, cre-
atinine and WBC, were similar in both groups. Patients in
group 3 had higher LDL-cholesterol levels compared with
patients in group 1 (149.1 ± 37.6 versus 130.1 ± 28.9 mg/dL,
respectively; p < 0.05).
Male patients had higher plasma IMD levels compared
to females (142.3 ± 16.8 versus 135.3 ± 18.7 pg/mL, re-
spectively; p < 0.01). In addition, the plasma IMD concen-
tration was elevated in current smokers (143.4 ± 16.8
versus 137.3 ± 18.3 pg/mL, respectively; p = 0.02). Presence
of other cardiovascular risk factors such as hypertension,
diabetes mellitus, and hyperlipidemia did not affect plasma
IMD levels (Table 2). A positive correlation was observed
between plasma IMD levels and age (rs = 0.255, p < 0.01).
The plasma IMD concentration in patients with
CAD was significantly higher than in patients without
CAD (157.7 ± 9.6, 134.8 ± 11.9, and 117.6 ± 7.9 pg/mL
in Groups 3, 2, and 1, respectively; p < 0.01) (Table 3,
Figure 1). In addition, plasma IMD levels were correlated
with the vessel, Gensini, and SYNYAX scores (rs = 0.710,
rs = 0.742, and rs = 0.296, respectively; p < 0.01) (Figure 2a,
b, and c).
ROC curve was generated for sensitivity and specificity
with the respective areas under the curve (AUC) for the
plasma IMD concentration. The diagnostic value for
plasma IMD levels in discriminating patients with ≥ 50%
coronary stenosis in at least one of the coronary arteries
Table 1 Patient demographics, clinical and laboratory characteristics
Patients without CAD
(Group 1) (n = 48)
Patients with <50% coronary stenosis
(Group 2) (n = 111)
Patients with ≥50% coronary stenosis
(Group 3) (n = 79)
Age (years) 52.5 ± 8.8 58.0 ± 9.9* 62.6 ± 9.1*#
Male gender (%) 14 (29.2%) 54 (48.6%)* 55 (69.6%)*#
BMI (kg/m2) 30.6 ± 4.6 29.0 ± 4.9 28.7 ± 5.1
Waist circumference (cm) 100.9 ± 10.2 101.4 ± 9.2 102.1 ± 8.2
Current smoker 10 (20.8%) 28 (25.2%) 26 (32.9%)
Hypertension (%) 23 (47.9%) 61 (54.9%) 34 (43.0%)
Diabetes mellitus (%) 12 (25.0%) 35 (31.5%) 24 (30.4%)
Dyslipidemia (%) 10 (20.8%) 28 (25.2%) 16 (20.2%)
SBP (mmHg) 135.8 ± 22.6 138.0 ± 22.8 137.5 ± 20.9
DBP (mmHg) 78.2 ± 8.3 79.2 ± 10.5 79.5 ± 9.3
Glucose (mg/dL) 118.2 ± 57.5 114.9 ± 31.1 117.9 ± 44.4
Creatinine (mg/dL) 0.7 ± 0.1 0.8 ± 0.2 0.8 ± 0.2
WBC (×103/mL) 7.8 ± 1.8 7.4 ± 1.8 7.5 ± 1.7
Total cholesterol (mg/dL) 204.1 ± 30.5 208.7 ± 28.4 217.3 ± 40.2
LDL cholesterol (mg/dL) 130.1 ± 28.9 140.7 ± 32.0 149.2 ± 37.6*
HDL cholesterol (mg/dL) 41.5 ± 13.5 39.0 ± 8.7 38.4 ± 10.3
Triglyceride (mg/dL) 150.2 ± 62.1 160.5 ± 58.3 153.7 ± 55.2
BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, WBC: White blood cell count, LDL: Low density lipoprotein, HDL: High
density lipoprotein.
*p < 0.05 versus group 1.
#p < 0.05 versus group 2.
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0.955, Figure 3). If we determined a concentration of
147.70 pg/mL as cutoff value for plasma IMD, we could
predict the presence of CAD with significant stenosis with




Male 142.3 ± 16.8 0.002
Female 135.3 ± 18.7
Smoking habit
Current smoker 143.4 ± 16.8 0.02
Nonsmokers and ex-smokers 137.3 ± 18.3
Hypertension
Present 138.7 ± 17.7 0.71
Absent 139.6 ± 19.0
Diabetes mellitus
Present 140.7 ± 16.9 0.33
Absent 138.2 ± 18.9
Hyperlipidemia
Present 138.1 ± 18.3 0.78
Absent 139.0 ± 19.4predictive value was 88.7%. The diagnostic value for plasma
IMD levels in discriminating patients with normal coronary
arteries, who underwent coronary angiography with
suspicion of CAD, was also high. A plasma IMD level
of <126.60 pg/mL could discriminate a patient with normal
coronary arteries from patients with angiographically
proven CAD with a sensitivity and specifity of 84.7%, and
83.3% respectively.
Multivariate linear logistic regression analysis was per-
formed to estimate the effects of plasma IMD levels to-
gether with other cardiovascular risk factors such as age,
male gender, smoking, BMI, waist circumference, hyper-
tension, diabetes, dyslipidemia and LDL-cholesterol levels
on the presence of CAD (Table 4). Plasma IMD levels
were independently associated with the presence of CAD
(β = 0.267, BE = 1.305, p < 0.001).
Discussion and conclusion
Roh and colleagues identified a new peptide that possesses
similar characteristics with adrenomedullin and named it
IMD due to its primarily expression in the intermediate
lobe of the anterior pituitary glands [16]. This peptide is a
member of the CGRP superfamily, which is well known as
an endocrine and neurocrine integrator of homeostasis in
the cardiovascular system [17]. Subsequent preclinical and
human studies reported that IMD is also localized in the
left ventricular myocytes, pericardial adipocytes, in vascular
Table 3 Angiographical characteristics of the study population and plasma IMD levels of the groups
Patients without CAD
(Group 1) (n = 48)
Patients with <50% coronary stenosis
(Group 2) (n = 111)
Patients with ≥50% coronary stenosis
(Group 3) (n = 79)
Gensini score 0 17.2 ± 14.3 152.2 ± 91.7
Number of diseased vessels
0 48 50 0
1 - - 18
2 - - 23
3 - - 23
4 - - 2
Vessel score 0 0 2.2 ± 1.0
Location of stenosis (≥ 50%)
LMCA - - 9
LAD - - 58
LCx - - 51
RCA - - 53
SYNTAX score - - 15.1 ± 7.8
Plasma Intermedin (pg/mL) 117.6 ± 7.9 134.8 ± 11.9* 157.7 ± 9.6*,#
LMCA: Left main coronary artery, LAD: Left coronary artery, LCx: Left circumflex artery, RCA: Right coronary artery.
*p < 0.01 compared to group 1.
#p < 0.01 compared to group 2.
Data were presented as mean ± standard deviation.
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and tubular cells [6].
Increased expression of IMD in animal models of
cardiovascular diseases such as myocardial hypertrophy,
chronic hypoxia-induced pulmonary hypertension, ischemia-
reperfusion injury, hypertension and heart failure suggested
a key role of IMD in cardiac pathophysiology [5,6,18,19].
The robust increase in expression of the peptide in hyper-Figure 1 Plasma intermedin levels among the study groups. Data weretrophied and ischemic myocardium indicates an import-
ant protective role for IMD as an endogenous counter-
regulatory peptide in the heart. This was underlined by the
observation that progression of atherosclerotic plaque in
ApoE null mice was terminated with exogenous adminis-
tration of IMD [9].
On cell level it has been shown that intermedin pro-
tects human macrovascular, microvascular, and cardiacpresented as mean ± standard deviation (CAD: Coronary artery disease).
Figure 2 Plasma intermedin concentration plotted against vessel (a), Gensini (b), and SYNTAX (c) scores.
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AM(1)-receptor signaling [20]. Furthermore, IMD exerts
potent cardioprotective effects against acute rat ischemic
injury [21], inhibiting endoplasmic reticulum stress via
PI3 kinase-Akt signaling [22], and activating cardioprotec-
tive Akt/GSK-3beta signaling, decreasing mitochondrial-
mediated myocardial apoptosis [23].
Considering the cardioprotective effects of endogenous
and exogenous IMD, we assumed that plasma IMD
levels might be upregulated in stable patients with suspi-
cious CAD, countering the detrimental effects of endo-
thelial dysfunction and oxidative stress related to CAD,
even in an early phase of atherosclerotic changes.
So far, plasma levels of IMD in patients with CAD were
investigated only in a few studies [10,11]. Qin et al. demon-
strated that plasma IMD levels were markedly enhanced in
forty-one patients, who underwent coronary angiography
with suspected acute coronary syndrome (UAP and acuteMI), compared to younger healthy controls [10]. In this pa-
tient collective, high age, elevated systolic blood pressure,
concentrations of brain natriuretic peptide (BNP), high-
sensitivity C-reactive protein (hsCRP), creatinine kinase-MB
(CK-MB), and Gensini score were correlated to plasma
IMD levels. A similar study investigated the serial changes
in plasma IMD levels in patients with acute ST-segment ele-
vation MI, stable CAD patients, and healthy controls [11].
Besides the detection of higher values of plasma IMD in pa-
tients with acute MI compared to stable patients with CAD,
plasma IMD concentration was gradually elevated in pa-
tients with CAD compared to healthy to controls (148.8 ±
6.0 versus 125.9 ± 9.2 pg/mL, p < 0.05). Significant correla-
tions between IMD and diverse markers of oxidative stress
such as superoxide dismutase and malonaldehyde during
the course of acute MI supported the hypothesis that IMD
might be released to protect the heart from deleterious ef-
fects related to ischemia reperfusion injury. The lack of an
Figure 3 Receiver-operating characteristic (ROC) analysis for plasma intermedin for the discrimination of patients with ≥50% stenosis
at least in one of the coronary arteries from patients with normal coronary anatomy and <50% stenosis.
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injury such as CK-MB, Troponin-T and BNP was explained
by the insensitivity of IMD for early diagnosis of MI. Thus
IMD seems to be more a biomarker of a chronic process,
namely atherosclerosis, helping to determine the presence
and extent of CAD in a stable patient collective with suspi-
cious CAD.Table 4 Multivariate logistic regression analysis of
various variables (demographical features, co-morbidities
and plasma intermedin levels) which determined as
predictors of coronary artery disease in univariate
analyses (R2 = 0.63)
Variables β Coefficient Odds (95% C.I.) p
Current smoker −19.60 0 1
BMI −0.01 0.99 (0.57–1.70) 0.96
Hypertension −0.69 0.50 (0.03–8.03) 0.62
Age 0.05 1.05 (0.89–1.23) 0.56
Dyslipidemia −1.27 0.28 (0–20.74) 0.56
Male gender −1.80 0.16 (0.01–2.16) 0.17
LDL-cholesterol 0.02 1.02 (0.99–1.05) 0.18
Diabetes mellitus 2.08 8.03 (0.66–98.0) 0.10
Waist circumference - 0.10 0.90 (0.81–1.01) 0.07
Intermedin 0.27 1.30 (1.11–1.53) <0.001
BMI: Body mass index, LDL: low-density lipoprotein.Thus our aim was to evaluate the predictive strength
of IMD in selecting stable patients with CAD from
healthy individuals, who were admitted to first time
diagnostic angiography. We demonstrated that plasma
IMD levels were enhanced in patients with angiograph-
ically confirmed CAD compared to patients with normal
coronary angiograms. In addition, plasma IMD levels
were significantly higher in patients with critical coron-
ary artery stenosis (≥ 50%) than in patients with non-
critical (< 50%) coronary lesions. There was a positive
and significant correlation between severity and extent
of CAD assessed with angiographic indexes and plasma
IMD levels. Circulating levels of IMD were independ-
ently associated with the presence of CAD. Possible po-
tential implications of this study could be regarded as
follows:
– measurement of serum IMD levels could support
the clinician about the presence and severity of
CAD before coronary angiography.
– unnecessary coronary angiographies could be
prevented by measuring serum IMD levels.
– as a biomarker of atherosclerotic progression,
patients with elevated serum IMD levels could be
treated more intensely, for example high dose
statins, renin/angiotensin system blockers and
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patients with elevated serum IMD levels could be
reasonable to early detection and treatment of
atherosclerotic involvement.
Elevated levels of IMD in patients with CAD seem to be
associated with atherosclerotic development, even in pa-
tients with a subclinical disease. Besides, correlations be-
tween IMD and indices of CAD extent and severity could
be regarded as increased expression of IMD in compensa-
tory fashion to the degree of atherosclerotic involvement.
Second, for the first time in the literature, our results re-
vealed that plasma IMD levels were independently associ-
ated with the presence of CAD. Although we demonstrated
significant correlations between the plasma IMD level and
Gensini score similar to previous studies, IMD appeared as
an independent variable associated with the presence of
CAD when we evaluated the presence of CAD with other
variables such as age, male gender, smoking, and LDL chol-
esterol in a multivariate logistic regression analysis. Further-
more, we demonstrated the essential attributes of IMD
testing such as sensitivity, specifity, positive and negative
predictive values for the first-time. These results suggested
that IMD could be used as a biomarker to discriminate pa-
tients with CAD and predict those with severe disease who
require early and intensive therapeutic intervention.
Although the correlation between serum IMD levels
and angiographic indices such as vessel and Gensini score
was strong (rs = 0.710 and rs = 0.742, respectively), a dim-
inution was stood out in correlation coefficient for SYN-
TAX score (rs = 0.296). The SYNTAX score is a relatively
new index compared to the others and primary focus on
coronary anatomy, which includes defining the coronary
dominance and characterizing the presence and features
of chronic total occlusions, trifurcations, bifurcations,
aorto-ostial lesions, severe tortuosity, long lesions, heavy
calcification, thrombus and/or diffuse disease [14]. The
SYNTAX score originated from the landmark Synergy be-
tween PCI with Taxus and Cardiac Surgery (SYNTAX)
trial in 2009 which sought to establish whether coronary
artery bypass grafting (CABG) or percutaneous coronary
intervention (PCI) was the standard of care for patients
with three-vessel or left main coronary artery disease. Al-
though the score is used primarily to risk-stratify these
complex patients, the use of the score for appropriate risk
stratification in order to determine the optimal revascular-
ization strategy in all CAD types are very popular now-
adays. In our study, the mean SYNTAX score was very
low (15.1 ± 7.8) due to a few number of patients with com-
plex disease (for example, 2 patients with LMCA stenosis).
We assume that poor correlation between SYNTAX score
and serum IMD levels was resulted from relatively low
SYNTAX scores and limited number of patients with high
(>22) SYNTAX score in our study.The main limitation of our study was that other markers
of atherogenesis such as hsCRP, chemotactic molecules,
interleukin-6 and growth differentiation factor-15 were
not determined. Other pathologies that could potentially
elevate serum IMD levels such as gastrointestinal, pituit-
ary, other organ or body systems did not take into
account. Also, patients were not investigated for other po-
tential sites of atherosclerosis, such as carotid artery,
thoraco-abdominal aorta, renal arteries, and peripheral
vascular bed. Although potential underlying mechanisms
proposed to explain the elevated plasma IMD levels in pa-
tients with CAD were discussed, the exact mechanism re-
mains unclear. Additionally, this was a cross-sectional
study and thus, the clinical impact of the results should be
assessed by clinical follow-up studies.
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